99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of MEIP Investors. Click "Join this Class Action" above.


MEI Pharma, Inc.

Join Class Action »

Zhang Investor Law announces  a class action lawsuit on behalf of shareholders who bought shares of MEI Pharma, Inc. (NASDAQ: MEIP) from August 2, 2017 through July 1, 2020 (the “Class Period”). The lawsuit seeks to recover damages for MEI Pharma, Inc. investors under the federal securities laws.

If you bought MEI Pharma, Inc. securities between August 2, 2017 through July 1, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against MEI Pharma, Inc. – MEIP

New York, N.Y., September 11, 2020. Zhang Investor Law announces  a class action lawsuit on behalf of shareholders who bought shares of MEI Pharma, Inc. (NASDAQ: MEIP)  between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”).

To join the MEIP class action, go to http://zhanginvestorlaw.com/cases/mei-pharma-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take not action at this time.

According to the lawsuit,  throughout the Class Period (1) MEI Pharma overstated Pracinostat’s potential efficacy as an acute myeloid leukemia (“AML”), treatment for the target population; (2) consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; (3) all the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company’s financial condition and prospects for Pracinostat; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 9, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/mei-pharma-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.